{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:23Z","timestamp":1792181723799,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201700082C"],"award-info":[{"award-number":["HHSN272201700082C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201700082C"],"award-info":[{"award-number":["HHSN272201700082C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The objective of this study is to evaluate the immunogenicity of adjuvanted monovalent rabies virus (RABV)\u2013based vaccine candidates against Ebola virus (FILORAB1), Sudan virus (FILORAB2), Marburg virus (FILORAB3), Lassa virus (LASSARAB1), and combined trivalent vaccine candidate (FILORAB1\u20133) and tetravalent vaccine candidate (FILORAB1\u20133 and LASSARAB) in nonhuman primates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-four Macaca fascicularis were randomly assigned into 6 groups of 4 animals. Each group was vaccinated with either a single adjuvanted vaccine, the trivalent vaccine, or the tetravalent vaccine at days 0 and 28. We followed the humoral immune responses for 1 year by antigen-specific enzyme-linked immunosorbent assays and RABV neutralization assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>High titers of filovirus and\/or Lassa virus glycoprotein-specific immunoglobulin G were induced in the vaccinated animals. There were no significant differences between immune responses in animals vaccinated with single vaccines vs trivalent or tetravalent vaccines. In addition, all vaccine groups elicited strong rabies neutralizing antibody titers. The antigen-specific immune responses were detectable for 1 year in all groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In summary, this study shows the longevity of the immune responses up to 365 days for a pentavalent vaccine\u2014against Ebola virus, Sudan virus, Marburg virus, Lassa virus, and RABV\u2014using a safe and effective vaccine platform.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab014","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T05:57:56Z","timestamp":1610171876000},"page":"995-1004","source":"Crossref","is-referenced-by-count":24,"title":["Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces Long-term Immunity in Nonhuman Primates"],"prefix":"10.1093","volume":"224","author":[{"given":"Drishya","family":"Kurup","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Scher","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Yankowski","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnaMarie","family":"Testa","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Keshwara","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Abreu-Mota","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ferguson","sequence":"additional","affiliation":[{"name":"AlphaGenesis Inc, Yemassee, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"AlphaGenesis Inc, Yemassee, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Exxell BIO Inc, Saint Paul, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wirblich","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-9405","authenticated-orcid":false,"given":"Matthias J","family":"Schnell","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"},{"name":"Jefferson Vaccine Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"2021091718325461400_CIT0001","author":"World"},{"key":"2021091718325461400_CIT0002","author":"Centers for Disease Control and Prevention"},{"key":"2021091718325461400_CIT0003","author":"World Health Organization"},{"key":"2021091718325461400_CIT0004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/trstmh\/tru009","article-title":"Constraints in the diagnosis and treatment of Lassa fever and the effect on mortality in hospitalized children and women with obstetric conditions in a rural district hospital in Sierra Leone","volume":"108","author":"Dahmane","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021091718325461400_CIT0005","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Richmond","year":"2003","journal-title":"BMJ"},{"key":"2021091718325461400_CIT0006","doi-asserted-by":"crossref","first-page":"e0205884","DOI":"10.1371\/journal.pone.0205884","article-title":"System dynamics modelling approach to explore the effect of dog demography on rabies vaccination coverage in Africa","volume":"13","author":"Chidumayo","year":"2018","journal-title":"PLoS One"},{"key":"2021091718325461400_CIT0007","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bull World Health Organ"},{"key":"2021091718325461400_CIT0008","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J Clin Invest"},{"key":"2021091718325461400_CIT0009","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u2206G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021091718325461400_CIT0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"2021091718325461400_CIT0011","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","article-title":"Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic","volume":"77","author":"McGettigan","year":"2003","journal-title":"J Virol"},{"key":"2021091718325461400_CIT0012","doi-asserted-by":"crossref","first-page":"43339","DOI":"10.1038\/srep43339","article-title":"The final (oral Ebola) vaccine trial on captive chimpanzees?","volume":"7","author":"Walsh","year":"2017","journal-title":"Sci Rep"},{"key":"2021091718325461400_CIT0013","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/infdis\/jiw231","article-title":"An inactivated rabies virus-based Ebola vaccine, FILORAB1, adjuvanted with glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge models","volume":"214","author":"Johnson","year":"2016","journal-title":"J Infect Dis"},{"key":"2021091718325461400_CIT0014","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/infdis\/jiv251","article-title":"Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses","volume":"212","author":"Willet","year":"2015","journal-title":"J Infect Dis"},{"key":"2021091718325461400_CIT0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.virusres.2014.11.028","article-title":"Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-Ebola vaccine","volume":"197","author":"Papaneri","year":"2015","journal-title":"Virus Res"},{"key":"2021091718325461400_CIT0016","doi-asserted-by":"crossref","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine","volume":"9","author":"Blaney","year":"2013","journal-title":"PLoS Pathog"},{"key":"2021091718325461400_CIT0017","doi-asserted-by":"crossref","first-page":"e01865-18","DOI":"10.1128\/JVI.01865-18","article-title":"A recombinant rabies virus expressing the Marburg virus glycoprotein is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model","volume":"93","author":"Keshwara","year":"2019","journal-title":"J Virol"},{"key":"2021091718325461400_CIT0018","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"2021091718325461400_CIT0019","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiz332","article-title":"Inactivated rabies virus-based Ebola vaccine preserved by vaporization is heat-stable and immunogenic against Ebola and protects against rabies challenge","volume":"220","author":"Kurup","year":"2019","journal-title":"J Infect Dis"},{"key":"2021091718325461400_CIT0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-020-00248-6","article-title":"Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2","volume":"5","author":"Kurup","year":"2020","journal-title":"NPJ Vaccines"},{"key":"2021091718325461400_CIT0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-019-0109-5","article-title":"Rabies-based vaccine induces potent immune responses against Nipah virus","volume":"4","author":"Keshwara","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2021091718325461400_CIT0022","doi-asserted-by":"crossref","first-page":"e02040-16","DOI":"10.1128\/JVI.02040-16","article-title":"One-Health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus","volume":"91","author":"Wirblich","year":"2017","journal-title":"J Virol"},{"key":"2021091718325461400_CIT0023","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J Virol"},{"key":"2021091718325461400_CIT0024","doi-asserted-by":"crossref","first-page":"e0146372","DOI":"10.1371\/journal.pone.0146372","article-title":"The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for TH1 induction","volume":"11","author":"Dubois Cauwelaert","year":"2016","journal-title":"PLoS One"},{"key":"2021091718325461400_CIT0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"key":"2021091718325461400_CIT0026","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bull World Health Organ"},{"key":"2021091718325461400_CIT0027","author":"National Institute of Allergy and Infectious Diseases"},{"key":"2021091718325461400_CIT0028","author":"Centers"},{"key":"2021091718325461400_CIT0029","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J Clin Invest"},{"key":"2021091718325461400_CIT0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2021091718325461400_CIT0031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5152\/tpa.2014.2206","article-title":"Vaccination in patients with immunosuppression","volume":"49","author":"Arvas","year":"2014","journal-title":"Turk Pediatri Ars"},{"key":"2021091718325461400_CIT0032","doi-asserted-by":"crossref","first-page":"e0192312","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS One"},{"key":"2021091718325461400_CIT0033","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","article-title":"Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site","volume":"15","author":"Howell","year":"2016","journal-title":"Cell Rep"},{"key":"2021091718325461400_CIT0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/inthealth\/ihu071","article-title":"Human rabies deaths in Africa: breaking the cycle of indifference","volume":"7","author":"Dodet","year":"2015","journal-title":"Int Health"},{"key":"2021091718325461400_CIT0035","author":"World Health Organization"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab014\/38499271\/jiab014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/6\/995\/40406245\/jiab014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/6\/995\/40406245\/jiab014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T18:33:54Z","timestamp":1631903634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/6\/995\/6075344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,1,9]]},"published-print":{"date-parts":[[2021,9,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab014","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,15]]},"published":{"date-parts":[[2021,1,9]]}}}